

1 **Title: Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with**
2 **or without exposure to SARS-CoV-2**

3
4 **Author names and affiliations:** María Noel Badano^{a,b}, Florencia Sabbione^{a,1}, Irene
5 Keitelman^{a,1}, Matias Pereson^a, Natalia Aloisi^b, Ana Colado^a, Victoria Ramos^a, Juan Manuel Ortiz
6 Wilczyński^a, Roberto Pozner^a, Luis Castillo^a, Georgina Wigdorovitz^a, María Marta E de Bracco^a,
7 Susana Fink^a, Roberto Chuit^c, Patricia Baré^{a,b}

8
9 ^a Instituto de Medicina Experimental (IMEX)-Consejo Nacional de Investigaciones Cientificas y
10 Tecnicas (CONICET), Academia Nacional de Medicina. Postal address: J.A. Pacheco de Melo
11 3081, CABA 1425, Buenos Aires, Argentina.

12 ^b Instituto de Investigaciones Hematológicas (IIHEMA), Academia Nacional de Medicina. Postal
13 address: J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina.

14 ^c Instituto de Investigaciones Epidemiológicas (IIE), Academia Nacional de Medicina. Postal
15 address: J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires, Argentina.

16
17 ¹ These authors contributed equally to this research.

18
19 **Corresponding author:** Patricia Baré. Telephone number: +5491154975179. E-mail:
20 patobare@gmail.com Postal address: J.A. Pacheco de Melo 3081, CABA 1425, Buenos Aires,
21 Argentina. ORCID identifier: 0000-0002-6348-428X

22
23
24
25

26 **Abstract**

27 SARS-CoV-2-specific humoral response was analyzed over time in a group of healthcare
28 workers with or without exposure to SARS-CoV-2, who underwent vaccination with BBIBP-CorV
29 (Sinopharm) vaccine in Argentina.

30 Seroconversion rates in unexposed subjects after the first and second doses were 40% and
31 100%, respectively, showing a significant increase in antibody concentrations from dose 1 to
32 dose 2 ($p < 0.0001$).

33 The highest antibody concentrations were found in younger subjects and women, remaining
34 significantly associated in a multivariable linear regression model ($p = 0.005$).

35 A single dose of the BBIBP-CorV vaccine induced a strong antibody response in individuals with
36 prior SARS-CoV-2 infection, while a second dose did not increase this response. A sharp
37 increase in antibody concentrations was observed following SARS-CoV-2 infection in those
38 participants who became infected after the first and second doses ($p = 0.008$).

39 Individuals with SARS-CoV-2 exposure prior to vaccination showed significantly higher anti-
40 spike IgG antibody levels, at all-time points, than those not exposed ($p < 0.001$). Higher antibody
41 titers were induced by a single dose in previously SARS-CoV-2 infected individuals than those
42 induced in naïve subjects by two doses of the vaccine ($p < 0.0001$). Three months after the
43 second dose both groups showed a decline in antibody levels, being more abrupt in unexposed
44 subjects.

45 Overall, our results showed a trend towards lower antibody concentrations over time following
46 BBIBP-CorV vaccination. Sex and age seem to influence the magnitude of the humoral
47 response in unexposed subjects while the combination of exposure to SARS-CoV-2 plus
48 vaccination, whatever the sequence of the events was, produced a sharp increase in antibody
49 levels.

50 Evaluation of the humoral responses over time and the analysis of the induction and persistence
51 of memory B and T cell responses, are needed to assess long-term immune protection induced
52 by BBIBP-CorV vaccine.

53 **Keywords**

54 SARS-CoV-2 infection, BBIBP-CorV, anti-spike antibodies, Humoral response

55

56 **Introduction**

57 In early 2020, the Beijing Institute of Biological Products developed an inactivated coronavirus
58 vaccine called BBIBP-CorV (Sinopharm). This vaccine was authorized for emergency use on
59 February 22nd 2021 by the Ministry of Health of Argentina and on May 7th 2021 by the World
60 Health Organization (WHO), giving the approval for this vaccine to be rolled out globally with an
61 efficacy estimate of 78.1%.

62 BBIBP-CorV is an inactivated vaccine consisting of virus particles that have been grown in
63 culture and then inactivated to lose the ability to produce disease, while still stimulating an
64 immune response. This vaccine was proven to be safe, immunogenic and effective in adults in
65 phase 1/2 and phase 3 trials [1,2]. Recently it was also shown to be safe and immunogenic in
66 people less than 18 years of age in a phase 1/2 trial [3]. Immunogenicity of the BBIBP-CorV
67 vaccine was assessed by measuring neutralizing antibody responses, and no data are available
68 about cellular memory response. Therefore, information on the induction and persistence of
69 memory B and T cell responses, along with the evaluation of the humoral responses over time
70 are needed to estimate the long-term immune protection against SARS-CoV-2 conferred by
71 BBIBP-CorV vaccine.

72 In Argentina, BBIBP-CorV vaccine is one of the three most administered along with the Sputnik
73 V (Gamaleya NRCEM) and ChAdOx1 nCoV-19 (University of Oxford/AstraZeneca) vaccines.

74 Hence, in the current work we evaluated SARS-CoV-2-specific humoral response over time in a

75 group of healthcare workers with or without exposure to SARS-CoV-2, who underwent
76 vaccination with BBIBP-CorV vaccine in Argentina.

77

78 **Materials and methods**

79

80 **Study design and participants**

81 An ongoing longitudinal observational cohort study, started in February 2021 among healthcare
82 workers from the Academia Nacional de Medicina, is being conducted to measure humoral and
83 cellular responses over time after vaccination against COVID-19.

84 A group of 82 individuals who underwent vaccination with BBIBP-CorV vaccine was included.

85 Among them, 66 subjects had no clinical history of SARS-CoV-2 infection, 8 individuals had a
86 prior SARS-CoV-2 infection and 8 subjects got infected between doses or after vaccination: 4
87 more than 14 days after the first dose, 2 immediately after the second dose and 2 more than 14
88 days after the second dose. All SARS-CoV-2 exposed subjects had mild disease based on
89 WHO classification [4].

90 As the BBIBP-CorV vaccine in Argentina was first authorized only for people less than 60 years
91 old, most of our population was below this age, with the exception of 4 individuals (Table 1).

92 With the aim of immunizing the largest number of people in the shortest time, second doses of
93 vaccines were deferred in Argentina and, therefore, most of the individuals in our study group
94 received their second dose 54 days after the first shot, instead of the original two-dose schedule
95 21 days apart.

96 Blood samples were drawn 21 to 30 days after the first (T1) and second (T2) doses, and three
97 months after dose 2 (T3), to measure humoral response over time. For those subjects who had
98 been infected by SARS-CoV-2 after the first and second doses, blood samples were also
99 obtained 21 to 30 days after the SARS-CoV-2 infection. Plasma or serum samples were

100 obtained immediately after centrifugation of the peripheral blood and stored in aliquots at -20°C
101 until used.

102 This study was approved by the local Ethics Committee of the Academia Nacional de Medicina
103 and written informed consent was obtained from each participant.

104

105 **SARS-CoV-2 antibody ELISA**

106 SARS-CoV-2 spike-specific IgG antibodies were measured using the ELISA test COVIDAR
107 according to the manufacturer's instructions (Laboratorios Lemos S.R.L, Buenos Aires,
108 Argentina) [5]. The plates of the assay are coated with a purified mixture of the spike protein
109 and the receptor binding domain (RBD) of the SARS-CoV-2 virus. Applying the criteria used for
110 the qualitative assay, by means of a cut-off value (the mean OD450 nm value of the Negative
111 Control + 0.150) \pm 10%, samples were considered as reactive, non-reactive or inconclusive.
112 Antibody concentrations to SARS-CoV-2 spike protein expressed as International Units/mL
113 (IU/mL) were determined by constructing a calibration curve with serial dilutions of the standard
114 included in the immunoassay kit (400 IU/ml, reactive human serum adjusted to WHO First
115 International Standard for human immunoglobulin against SARS-CoV-2, NIBSC Code 20/136,
116 version 2.0 of 12/17 / 2020). Each sample was properly diluted to fit an OD 450 nm within the
117 linear range of the calibration curve. Antibody concentrations were obtained by interpolating the
118 OD 450 nm value for each sample into the calibration curve.

119

120 **Statistical analysis**

121 Unpaired t test or Mann-Whitney test were used to assess differences in quantitative variables
122 between two groups. Paired Wilcoxon signed-rank test was used to compare antibody levels
123 before and after SARS-CoV-2 infection in subjects infected after the first and second doses.
124 Categorical data were analyzed by the Fisher's exact test. Multiple linear regression was
125 performed to test potential associations of demographic variables (age and sex) and

126 seroconversion after the first dose, with the magnitude of humoral immune response in
127 unexposed subjects, by calculating the linear regression coefficient (β) with 95% confidence
128 intervals (95% CI). For each time point studied, geometric mean concentrations (GMC) of anti-
129 spike-specific antibodies levels with 95% CI were calculated. In all cases, a value of $p < 0.05$
130 was considered indicative of a significant difference. All data analyses were performed using the
131 GraphPad 9.1.2 Prism software (GraphPad Software, San Diego, CA, USA).

132

133 **Results**

134

135 **Antibody response in unexposed subjects**

136 SARS-CoV-2-specific humoral response was analyzed in 66 SARS-CoV-2 naïve individuals
137 who received the two doses of BBIBP-CorV vaccine. Median age of participants was 43 (26-80)
138 and 76 % were women (Table 1). Twenty-six of 65 (40%) of the participants showed detectable
139 antibody titers after the first dose (T1) with a GMC of 43.6 IU/ml (95% CI: 30.3-62.8). After the
140 second dose (T2), all 60 tested subjects (100%) developed IgG anti-spike-specific antibodies
141 (GMC: 377.0 IU/ml; 95% CI: 324.3-438.3), showing a significant increase in antibody titers from
142 T1 to T2 ($p < 0.0001$). Three months after the second shot (T3), the GMC dropped to 125.4 IU/ml
143 (95% CI: 88.2-178.4) with antibody levels significantly lower compared to those present in T2
144 ($p < 0.0001$), but still significantly higher than those corresponding to T1 ($p < 0.0001$) (Figure 1A).
145 Higher antibody values were observed both at T2 ($p = 0.07$) and T3 ($p = 0.03$), in those subjects
146 who seroconverted after the first dose compared to those who did not.
147 Lack of seroconversion after the first shot could not be associated with age or sex. However,
148 after the second dose, subjects younger than 50 years old displayed significantly higher
149 antibody concentrations than those over 50 ($p = 0.01$) (Figure 1B). In addition, higher antibody
150 levels were observed in women compared to men, after the first ($p = 0.01$) and second doses

151 ($p=0.02$) (Figure 1C). No differences were observed in the median ages between men and
152 women ($p=0.9$). A multivariable linear regression analysis confirmed these result ($p=0.005$),
153 showing that older age and male sex were significantly and inversely associated with anti-spike
154 antibody levels at T2 (β_1 (≥ 50 years):-158.5; 95% CI: -280.5-36.47; $p=0.01$; β_2 (Male):-128;
155 95% CI: -247.2-8.784; $p=0.03$). As 76% in our study group were women, further analyses are
156 needed to confirm this observation.

157

158 **SARS-CoV-2 infected subjects**

159 Antibody responses were also analyzed in a group of 16 individuals who were infected with
160 SARS-CoV-2 at different time points: before vaccination ($n=8$), after the 1st dose ($n=4$) and after
161 the 2nd dose ($n=4$).

162 Antibody levels were analyzed longitudinally in 5 individuals with prior SARS-CoV-2 infection
163 who got infected 4 to 8 months before receiving the vaccine (Table 1). All revealed
164 seroconversion after the infection but one had no detectable antibodies at the time of receiving
165 the first shot. The GM of IgG concentrations before vaccination (T0) was 203.2 IU/ml (95% CI:
166 42.9-962.4) and increased to 761.7 IU/ml (95% CI: 381.1-1522) after the first dose, showing
167 detectable antibodies in all participants ($p=0.06$). Despite the small number of individuals to
168 draw strong conclusions, no significant differences were observed in antibody levels between
169 T1 and T2, reaching a GMC of 719.9 IU/ml (95% CI: 264.6-1959) at T2. Although there was a
170 trend towards lower values three months after the second dose (GMC: 484.4 IU/ml; 95% CI:
171 147.3-1593), antibody levels did not significantly differ from those at T2 (Figure 2B).

172 Eight subjects became infected after the first or second dose of BBIBP-CorV vaccine. A sharp
173 increase in antibody concentrations was seen after the infection (GMC: 2883 IU/ml; 95% CI:
174 1618-5137), being significantly higher compared to those present before the infection (GMC:
175 78.8 IU/ml; 95% CI: 14.7- 423.7) ($p=0.008$) (Figure 2A). At T3, antibody concentrations
176 remained high in this group of individuals (GMC: 1200 IU/ml; 95% CI: 491.3-2932), showing a

177 trend towards lower values with similar levels to those observed at T3 in subjects infected with
178 SARS-CoV-2 before vaccination ($p=0.2$). Further analyses at 6 and 12 months after vaccination
179 would contribute to define the dynamics of the declining antibody titers in these particular
180 groups (infection plus vaccination).

181

182 **Comparison between unexposed and SARS-CoV-2 infected subjects**

183 Antibody levels at different time points were compared between vaccinated subjects with and
184 without prior SARS-CoV-2 infection. Individuals previously exposed to the virus displayed
185 significantly higher concentrations of antibodies at T1 ($p<0.0001$), T2 ($p<0.0001$) and T3
186 ($p=0.0003$) compared to unexposed participants (Figure 2B), showing GMCs 17.5-, 1.9- and
187 3.9-fold higher at T1, T2 and T3, respectively. As it was reported for other vaccine formulations
188 [6-9], antibody levels after one vaccine dose in previously infected participants were significantly
189 higher ($p<0.0001$) than those reached after two doses in unexposed subjects (Figure 2B).
190 Moreover, 3 months after the second dose individuals with prior SARS-CoV-2 infection still
191 showed significantly ($p=0.0007$) higher antibody concentrations than those seen at T2 in SARS-
192 CoV-2 naïve participants, when the peak in anti-spike-specific IgG antibody values occurred
193 (Figure 2B).

194

195

196 **Discussion**

197 In the current work, SARS-CoV-2-specific humoral response was analyzed in a group of
198 unexposed and SARS-CoV-2 exposed subjects before or after the first or second dose of
199 BBIBP-CorV vaccine. We observed that despite seroconversion rate after the first dose was low
200 (40%) in SARS-CoV-2 naïve individuals, the 100% of participants developed antibody
201 responses to BBIBP-CorV vaccine after the second dose. A decline in antibody levels was seen
202 3 months after dose 2, but remained higher compared to those present after the first dose. We
203 also observed that age and sex influenced antibody concentrations reached after vaccination,
204 since women and subjects under 50 years of age showed higher antibody levels than men and
205 subjects over 50 years.

206 SARS-CoV-2 spike-specific IgG antibodies were also quantified in SARS-CoV-2 infected
207 individuals. In agreement with other vaccine formulations [6-9], a single dose of BBIBP-CorV
208 vaccine induces a strong antibody response in participants previously exposed to the virus,
209 while a second dose appears not to increase this response. Three months after the second
210 dose, antibody levels remained high but showing a decreasing trend, in this group.

211 Measurement of SARS-CoV-2 spike-specific IgG antibodies in participants who became
212 infected after the first or second vaccine doses, showed that antibody levels increased following
213 SARS-CoV-2 infection and were significantly higher than those present before infection. Despite
214 antibody levels remained high three months after dose 2, a trend towards lower antibody values
215 was observed in this group. However, similar antibody concentrations were found at T3 between
216 subjects exposed to SARS-CoV-2 before vaccination and those exposed after the first or
217 second dose of BBIBP-CorV vaccine. These results suggest that exposure to SARS-CoV-2
218 increases antibody levels regardless of whether the infection occurs before, during or after
219 vaccination.

220 Comparison between vaccinated subjects with and without prior SARS-CoV-2 infection showed
221 that IgG anti-spike antibody levels were significantly higher in individuals with prior SARS-CoV-2

222 infection at all-time points studied. In line with other vaccine formulations [6-9], a single dose of
223 BBIBP-CorV vaccine in previously SARS-CoV-2 infected individuals induces higher antibody
224 concentrations than those seen in naïve subjects who received the two doses. Three months
225 after the second dose, antibody levels in individuals with prior SARS-CoV-2 infection are still
226 higher than those observed in SARS-CoV-2 naïve participants after the second shot, when the
227 antibody values peaked. While both groups showed a decline in antibody levels at T3 (3 months
228 after the second dose and 5 months after the first dose), this decrease was more abrupt in
229 unexposed subjects. These results suggest that, as a consequence of their higher antibody
230 responses following vaccination, individuals with prior SARS-CoV-2 infection would display
231 detectable antibodies in blood for longer periods than unexposed subjects. As this is an ongoing
232 study, IgG antibody titers will be measured at 6 and 12 months after vaccination to monitor the
233 humoral response over time, in the different groups studied.

234 Immune response after vaccination is usually monitored by the measurement of antibody levels
235 because is cheaper, easier and fast compared to immune techniques that detect and evaluate
236 the functional capacities of immune memory cells. Therefore, correlates of protection after
237 vaccination are generally determined by establishing a minimum threshold antibody level. So
238 far, the threshold needed to confer protection against SARS-CoV-2 virus after COVID-19
239 vaccination is unknown. In the current work, in spite of 100% seroconversion rate achieved with
240 a two-dose schedule of BBIBP-CorV vaccine, a decrease in antibody levels was seen over time.
241 However, although antibodies wane over time following vaccination, this does not necessarily
242 imply that immune memory response is lost and therefore, immune protection. In fact, we
243 recently showed the presence of hepatitis A virus (HAV)-specific memory CD4⁺ T cell responses
244 in 54% of pediatric individuals who had received a single dose of inactivated HAV vaccine 12
245 years before and lacked protective anti-HAV antibody levels (≥ 10 mIU/mL), suggesting that the
246 presence of immune memory cells could be contributing to the absence of new HAV outbreaks
247 in our country [10]. Thus, information about memory T and B cell responses mounted after

248 BBIBP-CorV vaccine and its persistence over time is needed. Ongoing experiments to study
249 SARS-CoV-2-specific memory cell responses in this cohort of BBIBP-CorV vaccinated
250 individuals are being performed by our lab.

251 The seroconversion rates 14 days after the first and second doses of the BBIBP-CorV vaccine
252 were reported to be 75% and 100%, respectively [1,2]. In the present work, seroconversion
253 rates were 40% and 100%, 21-30 days after the first and second doses, respectively. This could
254 be explained by the different methodologies used to evaluate seroconversion (binding versus
255 neutralizing antibody assays) or different timing in seroconversion of the cohorts evaluated. It is
256 important to emphasize that even though our group received the second dose more than 21
257 days apart, a seroconversion rate of 100% was achieved.

258 As reported, the magnitude of neutralizing antibodies induced by BBIBP-CorV vaccine was
259 higher in individuals up to 60 years compared to those aged 60 years and older [1]. In
260 agreement, we observed higher antibody concentrations after two doses of BBIBP-CorV
261 vaccine in subjects younger than 50 years compared to those older than 50 years.

262 An association between the magnitude of the humoral response after BBIBP-CorV vaccination
263 and sex has not been reported. In a recent work using SARS-CoV-2 proteins and peptides
264 microarrays to analyze the humoral response elicited by the inactivated vaccine, a trend
265 towards higher IgG anti-spike antibody signal was observed in women compared to men [11]. In
266 the present study, women showed significantly higher antibody levels compared to men, after
267 the first and second doses. These discrepancies could be explained by the difference in sample
268 size and proportion of women tested and/or the different techniques used to analyze SARS-
269 CoV-2 humoral responses. As the majority of individuals in our population were women, these
270 observations need to be confirmed

271 A higher seroconversion rate after the first dose and higher levels of anti-spike-specific
272 antibodies were found using the same ELISA test (COVIDAR-IgG) when evaluating the humoral
273 response induced following Sputnik V vaccination in unexposed subjects [8, and our

274 unpublished results]. However, Sputnik V vaccine only targets the spike protein, while
275 inactivated virus vaccines could theoretically target spike plus other viral proteins. Therefore, it
276 is possible that the humoral response induced by BBIBP-CorV vaccine is more diverse and
277 targets other antigens of the SARS-CoV-2. Indeed, a recent work showed that higher antibody
278 responses to the non-structural proteins NSP7, NSP8 and the RNA-dependent RNA
279 polymerase (RdRp), which are part of the viral replication complex, are induced in healthy
280 individuals following vaccination with BBIBP-CorV when compared to those observed in COVID-
281 19 recovered subjects [11]. However, it could also be possible that the Sputnik V vaccine
282 induces a stronger humoral response against the SARS-CoV-2 spike protein than that induced
283 by the BBIBP-CorV vaccine.

284 This study has some limitations. Most of the unexposed subjects have unknown serostatus prior
285 to vaccination. However, the low seroconversion rate after the first dose and the abrupt decline
286 in antibody levels 3 months after the second dose, strongly suggest that they were seronegative
287 at baseline. Antibody neutralization assays were not performed and therefore should be done to
288 estimate long-term protection after BBIBP-CorV vaccine. Despite the low number of SARS-CoV-
289 2 exposed subjects to draw strong conclusions, the same tendency for other vaccine platforms
290 was observed, showing that robust antibody responses are elicited after one shot of BBIBP-
291 CorV vaccine in individuals with prior infection.

292 In summary, in the present study we quantified anti-spike antibodies over time after vaccination
293 with BBIBP-CorV vaccine in terms of IU/ml, allowing assays from different laboratories to be
294 compared. Despite the 100% seroconversion rate achieved after the second dose, a decline in
295 anti-spike antibody levels was seen 3 months after dose 2. Several factors like sex, age and
296 exposure to SARS-CoV-2 seem to influence the magnitude of this humoral response, as the
297 highest antibody concentrations in unexposed subjects were seen in younger subjects and
298 women, and the combination of exposure to SARS-CoV-2 virus plus vaccination, whatever the
299 sequence of the events is, produces a sharp increase in antibody levels.

300 Overall, our results suggest that the evaluation of the humoral response over time, through the
301 measurement of the antibody levels against spike and other SARS-CoV-2 proteins along with
302 the neutralization titers, and the analysis of the induction and persistence of memory B and T
303 cell responses, are necessary to assess long-term immune protection induced by BBIBP-CorV
304 vaccine.

305

306 **Declaration of Competing Interest**

307 The authors declare that they have no known competing financial interests or personal
308 relationships that could have appeared to influence the work reported in this paper.

309

310 **Declaration of Author Contributions**

311 Conceptualization, MNB and PB, general coordination, MNB, FS, IK, RC and PB, collection of
312 blood samples and clinical data, MNB, FS, IK, MP, NA, AC, VR, JMOW, RP, LC, GW and PB,
313 determination of IgG anti-spike antibody concentrations, MNB, MP, NA, and PB, data curation
314 and analysis, MNB, MMEB, SF, RC and PB, writing – original draft, MNB and PB, Writing –
315 review & editing, MNB, FS, IK, MP, NA, AC, VR, JMOW, RP, LC, GW, MMEB, SF, Rc and PB.
316 All authors read and approved the final manuscript.

317

318

319 **Acknowledgments**

320 The authors thank Fabiana Alberto, Santiago Castera, Bárbara Giménez and Macarena
321 Asensio for collaboration with blood draws. The authors are grateful to the COVIDAR group for
322 providing ELISA antibody tests (COVIDAR-IgG). Some aspects of this work could not have
323 been fulfilled without the generous contribution of the Fundación René Baron, IHEMA, IIE and
324 Academia Nacional de Medicina who provide financial support to our ongoing research.

325

326 **References**

327

328 [1] Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an
329 inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled,
330 phase 1/2 trial. *Lancet Infect Dis.* 2021;21:39-51. [https://doi.org/10.1016/S1473-3099\(20\)30831-](https://doi.org/10.1016/S1473-3099(20)30831-8)
331 [8](https://doi.org/10.1016/S1473-3099(20)30831-8).

332 [2] Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2
333 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A
334 Randomized Clinical Trial. *JAMA.* 2021;326:35-45. <https://doi.org/10.1001/jama.2021.8565>.

335 [3] Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an
336 inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised,
337 double-blind, controlled, phase 1/2 trial. *Lancet Infect Dis.* 2021;S1473-3099(21)00462-X.
338 [https://doi.org/10.1016/S1473-3099\(21\)00462-X](https://doi.org/10.1016/S1473-3099(21)00462-X).

339 [4] World Health Organization. COVID-19 Clinical management: living guidance. WHO/2019-
340 nCoV/clinical/2021.1. 2021 Jan. 25.

341 [5] Ojeda DS, Gonzalez Lopez Ledesma MM, Pallarés HM, Costa Navarro GS, Sanchez L,
342 Perazzi B, et al. Emergency response for evaluating SARS-CoV-2 immune status,
343 seroprevalence and convalescent plasma in Argentina. *PLoS Pathog.* 2021;17:e1009161.
344 <https://doi.org/10.1371/journal.ppat.1009161>.

345 [6] Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF et al.
346 Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA
347 Vaccine. *N Engl J Med.* 2021;384:1372-4. <https://doi.org/10.1056/NEJMc2101667>.

348 [7] Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, et al. Antibody responses to
349 the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med.*
350 2021;27:981-4. <https://doi.org/10.1038/s41591-021-01325-6>.

- 351 [8] Rossi AH, Ojeda DS, Varese A, Sanchez L, Gonzalez Lopez Ledesma MM, Mazzitelli I et al.
352 Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single
353 dose. *Cell Rep Med.* 2021;2:100359. <https://doi.org/10.1016/j.xcrm.2021.100359>.
- 354 [9] Havervall S, Marking U, Greilert-Norin N, Ng H, Gordon M, Salomonsson AC et al. Antibody
355 responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously
356 infected with SARS-CoV-2. *EBioMedicine.* 2021;70:103523.
357 <https://doi.org/10.1016/j.ebiom.2021.103523>.
- 358 [10] Uruña A, Badano MN, González JE, Baré P, Fink S, Vizzotti C. Humoral and cellular
359 immune memory response 12 years after single dose vaccination against hepatitis A in
360 Argentinian children. 39th Annual Meeting of the European Society for Paediatric Infectious
361 Diseases; 2021 May 24-29; Geneva, Switzerland.
- 362 [11] Ma ML, Shi DW, Li Y, Hong W, Lai DY, Xue JB, et al. Systematic profiling of SARS-CoV-2-
363 specific IgG responses elicited by an inactivated virus vaccine identifies peptides and proteins
364 for predicting vaccination efficacy. *Cell Discov.* 2021; 7:67. [https://doi.org/10.1038/s41421-021-](https://doi.org/10.1038/s41421-021-00309-7)
365 [00309-7](https://doi.org/10.1038/s41421-021-00309-7).
- 366
- 367
- 368
- 369
- 370

371 **Figure captions**

372

373 **Fig. 1.** SARS-CoV-2-specific humoral response following vaccination with BBIBP-CorV in
374 SARS-CoV-2 naïve individuals. (A) SARS-CoV-2 spike-specific IgG antibodies were measured
375 21 to 30 days after the first (T1) and second (T2) doses, and three months after dose 2 (T3). (B)
376 IgG anti-spike antibody levels after dose 2 of BBIBP-CorV vaccine in subjects older and
377 younger than 50 years. (C) anti-spike IgG antibody concentrations after the first and second
378 doses of BBIBP-CorV vaccine in men and women. IgG anti-spike antibody concentrations are
379 shown in International Units/mL (IU/mL). Geometric means with 95% confidence intervals are
380 shown. *p* values were determined by Unpaired t test or Mann-Whitney test.

381

382 **Fig. 2.** SARS-CoV-2-specific humoral response in BBIBP-CorV vaccinated subjects with
383 exposure to SARS-CoV-2 virus. (A) IgG anti-spike antibody levels before and after SARS-CoV-2
384 infection in subjects infected after the first and second doses of BBIBP-CorV vaccine. (B)
385 Comparison of anti-spike IgG antibody concentrations measured 21 to 30 days after the first
386 (T1) and second (T2) doses, and three months after dose 2 (T3), between vaccinated subjects
387 with and without prior SARS-CoV-2 infection. IgG anti-spike antibody concentrations are shown
388 in International Units/mL (IU/mL). Geometric means with 95% confidence intervals are shown. *p*
389 values were determined by the Wilcoxon matched-pairs signed-rank test (A) and the Unpaired t
390 test or Mann-Whitney test (B).

391

392

393

394

395

396

Table 1. Characteristics of the study cohort

	Unexposed (n=66)	Prior SARS-CoV-2 infection (n=8)	SARS-CoV-2 infection after dose 1 (n=4)	SARS-CoV-2 infection after dose 2 (n=4)
General characteristics				
Age (years)	43 (26-80)	44 (33-51)	39 (26-48)	44 (29-51)
Sex, <i>n</i> (%)				
Female/Male	50/16 (76/24)	3/5 (38/62)	4/0 (100/0)	4/0 (100/0)
SARS-CoV-2-related characteristics				
Mild cases, <i>n</i>	0	8	4	4
Time since infection to dose 1 (months)	NA	6.5 (4-8)	NA	NA
SARS-CoV-2 infection after dose 1 (days)	NA	NA	49 (37-49)	NA
SARS-CoV-2 infection after dose 2 (days)	NA	NA	NA	12.5 (5-96)

Values are expressed as median (range) or *n* (%). *NA* not applicable

Figure 1




Figure 2

